Posted on 1/20/21
Moderna CEO's 9 Words That Could Mean Billions for the Biotech
Moderna (NASDAQ:MRNA) generated revenue of roughly $60 million in 2019. The company will post total revenue measured in the hundreds of millions of dollars for 2020. . . .
Posted on 1/20/21
Fulcrum Therapeutics Prices of Public Offering of Common Stock
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically . . .
Posted on 1/20/21
TCR Therapeutics Prices Public Offering of $140.0 Million of Common Stock
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for . . .
Posted on 1/20/21
Chimerix Proposes $75,000,000 Public Offering of Common Stock
DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and . . .
Posted on 1/20/21
Passage Bio Announces Launch of Proposed Public Offering
PHILADELPHIA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a genetic medicines company focused on developing transformative therapies for rare monogenic central nervous . . .
Posted on 1/20/21
Editas Medicine Announces Offering of Common Stock
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading gene editing company, today announced that it intends to offer and . . .
Posted on 1/20/21
Aclaris Announces Proposed Public Offering of Common Stock
WAYNE, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, . . .
Posted on 1/20/21
Syros Announces Proposed Offering of Common Stock
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it is offering to sell . . .
Posted on 1/20/21
Maryland Reports 53 Additional Coronavirus Deaths, 1,972 New Cases
Maryland officials on Tuesday reported 53 more deaths related to coronavirus, bringing the state’s total number of confirmed COVID-19 fatalities to 6,476.There are also 174 deaths . . .
Posted on 1/20/21
Holy Cross Health Names Stonish Pierce COO
Holy Cross Health has named Stonish Pierce, FACHE as Chief Operating Officer, effective January 25, 2021. “Stonish joins the Holy Cross Health leadership team with more . . .
Posted on 1/19/21
Fulcrum Therapeutics Proposes Public Offering of Common Stock
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically . . .
Posted on 1/19/21
Ortho Clinical Diagnostics Launch of IPO
Ortho Clinical Diagnostics Holdings plc, the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, . . .
Posted on 1/19/21
Signet Healthcare and Bionpharma Sell CoreRx
NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Signet Healthcare Partners and Bionpharma Inc today announced the sale of CoreRx, a global contract development and manufacturing . . .
Posted on 1/19/21
Thermo Fisher Scientific to Acquire Mesa Biotech
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc.,
Posted on 1/19/21
NeuroBo Pharmaceuticals Announces $10.0 Million Private Placement
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that it has entered into securities purchase agreements with certain institutional and accredited investors to . . .
Posted on 1/19/21
VERO Biotech Secures $50 Million Funding from Runway Growth Capital
VERO Biotech LLC, an Atlanta, Georgia-based biotechnology company focused on saving lives, alleviating suffering, and improving the health economics of care, today announced the close of . . .
Posted on 1/19/21
Royalty Pharma Acquires Royalty Interest in Seltorexant From Minerva Neurosciences
NEW YORK and WALTHAM, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Minerva Neurosciences, Inc. (Nasdaq: NERV) today announced that Royalty . . .
Posted on 1/19/21
Better Choice Company Closes Strategic Investment of $2.7 Million
NEW YORK, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Better Choice Company (OTCQX: BTTR) (“Better Choice”), an animal health and wellness company, today announced the closing of . . .
Posted on 1/19/21
Minerva Neurosciences and Royalty Pharma Announce Sale of Seltorexant Royalty for up to $155 Million
Minerva Neurosciences, Inc. (Nasdaq: NERV) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma
Posted on 1/19/21
TCR² Therapeutics Proposes Public Offering of Common Stock
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for . . .
Posted on 1/19/21
Beam Therapeutics Announces $260 Million Common Stock Investment from Multiple Investors
CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that . . .
Posted on 1/19/21
Helius Medical Technologies Regains Compliance with Nasdaq Listing Standards
NEWTOWN, Pa., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM), a neurotech company focused on neurological wellness, today announced that it received . . .
Posted on 1/19/21
Alimera Sciences Announces Preliminary Top-line Results for Fourth Quarter and Full-Year 2020
ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic . . .
Posted on 1/19/21
Verve Therapeutics Closes $94 Million Series B
Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced the successful completion of a $94 million Series B financing, led . . .
Posted on 1/19/21
Can the Pfizer and Moderna Vaccines Beat the New Coronavirus Strains?
Investors in Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) may have breathed a sigh of relief when the U.S. Food and Drug Administration granted the companies' coronavirus vaccines . . .
